BRIEF-Genmab Says Phase 3 Trial For Epcoritamab Did Not Reach Statistical Significance

Reuters01-17

Jan 16 (Reuters) - Genmab A/S GMAB.CO:

GENMAB ANNOUNCES TOPLINE RESULTS FOR EPCORITAMAB (DUOBODY® CD3XCD20) FROM PHASE 3 EPCORE® DLBCL-1 TRIAL IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
GENMAB ANNOUNCES TOPLINE RESULTS FOR EPCORITAMAB (DUOBODY® CD3XCD20) FROM PHASE 3 EPCORE® DLBCL-1 TRIAL IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
GENMAB: STUDY OS DID NOT REACH STATISTICAL SIGNIFICANCE
GENMAB: STUDY DEMONSTRATED AN OVERALL SURVIVAL OF HR: 0.96
GENMAB - CO AND ABBVIE WILL ENGAGE WITH GLOBAL REGULATORY AUTHORITIES TO DISCUSS NEXT STEPS
GENMAB: DATA IS ANTICIPATED IN 2026 FROM TWO PHASE 3 TRIALS

Source text: ID:nGNX9tbFD

Further company coverage: GMAB.CO

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2604137679?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-17 02:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2604137679","market":"nz","top_or_hot":-1,"title":"BRIEF-Genmab Says Phase 3 Trial For Epcoritamab Did Not Reach Statistical Significance","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Genmab Says Phase 3 Trial For Epcoritamab Did Not Reach Statistical Significance</title></head><body><p><span>Jan 16 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/GMAB\">Genmab A/S</a> <span>GMAB.CO</span>:</p><ul><li><p>GENMAB ANNOUNCES TOPLINE RESULTS FOR EPCORITAMAB (DUOBODY® CD3XCD20) FROM PHASE 3 EPCORE® DLBCL-1 TRIAL IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)</p></li><li><p>GENMAB ANNOUNCES TOPLINE RESULTS FOR EPCORITAMAB (DUOBODY® CD3XCD20) FROM PHASE 3 EPCORE® DLBCL-1 TRIAL IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)</p></li><li><p>GENMAB: STUDY OS DID NOT REACH STATISTICAL SIGNIFICANCE</p></li><li><p>GENMAB: STUDY DEMONSTRATED AN OVERALL SURVIVAL OF HR: 0.96</p></li><li><p>GENMAB - CO AND ABBVIE WILL ENGAGE WITH GLOBAL REGULATORY AUTHORITIES TO DISCUSS NEXT STEPS</p></li><li><p>GENMAB: DATA IS ANTICIPATED IN 2026 FROM TWO PHASE 3 TRIALS</p></li></ul><p>Source text: <span>ID:nGNX9tbFD</span></p><p>Further company coverage: <span>GMAB.CO</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Genmab Says Phase 3 Trial For Epcoritamab Did Not Reach Statistical Significance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Genmab Says Phase 3 Trial For Epcoritamab Did Not Reach Statistical Significance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-17 02:37</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Genmab Says Phase 3 Trial For Epcoritamab Did Not Reach Statistical Significance</title></head><body><p><span>Jan 16 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/GMAB\">Genmab A/S</a> <span>GMAB.CO</span>:</p><ul><li><p>GENMAB ANNOUNCES TOPLINE RESULTS FOR EPCORITAMAB (DUOBODY® CD3XCD20) FROM PHASE 3 EPCORE® DLBCL-1 TRIAL IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)</p></li><li><p>GENMAB ANNOUNCES TOPLINE RESULTS FOR EPCORITAMAB (DUOBODY® CD3XCD20) FROM PHASE 3 EPCORE® DLBCL-1 TRIAL IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)</p></li><li><p>GENMAB: STUDY OS DID NOT REACH STATISTICAL SIGNIFICANCE</p></li><li><p>GENMAB: STUDY DEMONSTRATED AN OVERALL SURVIVAL OF HR: 0.96</p></li><li><p>GENMAB - CO AND ABBVIE WILL ENGAGE WITH GLOBAL REGULATORY AUTHORITIES TO DISCUSS NEXT STEPS</p></li><li><p>GENMAB: DATA IS ANTICIPATED IN 2026 FROM TWO PHASE 3 TRIALS</p></li></ul><p>Source text: <span>ID:nGNX9tbFD</span></p><p>Further company coverage: <span>GMAB.CO</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0943347566.SGD","symbol_name":"安联收益及增长平衡基金AM H2-SGD","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260116:nTUA5BJHSV:1","article_id":"2604137679","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2604137679","pubTimestamp":1768588622,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Genmab Says Phase 3 Trial For Epcoritamab Did Not Reach Statistical SignificanceJan 16 (Reuters) - Genmab A/S GMAB.CO:GENMAB ANNOUNCES TOPLINE RESULTS FOR EPCORITAMAB (DUOBODY CD3XCD20) FROM PHA","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0943347566.SGD":"安联收益及增长平衡基金AM H2-SGD","LU2129689431.USD":"FRANKLIN GLOBAL INCOME \"A\" (USD) ACC","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","LU0128525929.USD":"TEMPLETON GLOBAL \"A\" (USD) ACC","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","LU2023251221.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"AM\" (USD) INC","ABBV":"艾伯维公司","LU0211327993.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (USD) ACC","IE00BVYPNW00.USD":"GUINNESS GLOBAL EQUITY INCOME \"C\" (USD) ACC","BK4588":"碎股","LU1989772840.SGD":"CPR Invest - Climate Action A2 Acc SGD-H","LU1551013425.SGD":"Allianz Income and Growth Cl AMg2 DIS H2-SGD","LU2237443549.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA SGD-H","LU0124676726.USD":"AB SICAV I - SUSTAINABLE US THEMATIC PORTFOLIO \"A\" (USD) ACC","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","LU1496350171.SGD":"FRANKLIN DIVERSIFIED BALANCED \"A\" (SGDHDG) ACC","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","LU0965508806.USD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (USD) INC","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","LU0122379950.USD":"贝莱德世界健康科学A2","LU2089283258.USD":"安联环球可持续基金Cl AM Dis","IE00BVYPNV92.GBP":"GUINNESS GLOBAL EQUITY INCOME \"C\" (GBP) ACC","LU0198837287.USD":"UBS (LUX) EQUITY SICAV - USA GROWTH \"P\" (USD) ACC","LU1037948541.HKD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"A\" (HKD) ACC","IE00BGHQF631.EUR":"GUINNESS GLOBAL EQUITY INCOME \"C\" (EUR) ACC","LU0985320562.USD":"NORDEA 1 GLOBAL STARS EQUITY \"BP\" (USD) ACC","LU0234570918.USD":"高盛全球核心股票组合Acc Close","BK4550":"红杉资本持仓","LU0820561909.HKD":"ALLIANZ INCOME AND GROWTH \"AM\" (HKD) INC","LU1244550221.USD":"FRANKLIN GLOBAL MULTI-ASSET  INCOME \"A\" (USDHEDGED) INC (M)","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","LU0417517546.SGD":"Allianz US Equity Cl AT Acc SGD","LU0912757837.SGD":"JPMorgan Investment Funds - Global Income A (mth) SGD-H","LU1718418525.SGD":"JPMorgan Investment Funds - Global Select Equity A (acc) SGD","BK4585":"ETF&股票定投概念","LU0472753341.HKD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"A\" (HKD) ACC","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU0069063385.USD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"A\" (USD) ACC","LU0545039389.USD":"BGF GLOBAL EQUITY INCOME \"A2\" ACC","LU0057025933.USD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"AX\" (USD) ACC","LU0098860793.USD":"FRANKLIN INCOME \"A\" INC","IE00BN8TJ469.HKD":"FTGF CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A\" (HKD) INC","LU0795875086.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD","LU1244550494.USD":"FRANKLIN GLOBAL MULTI-ASSET INCOME \"A\" (USDHEDGED) ACC","LU0689626769.HKD":"AB SICAV I - SUSTAINABLE US THEMATIC PORTFOLIO \"A\" (HKD) ACC","LU2129689605.HKD":"FRANKLIN GLOBAL INCOME \"A\" (HKD) INC","LU0289739343.SGD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"A\" (SGD) ACC","LU2087621335.USD":"ALLSPRING GLOBAL FACTOR ENHANCED EQUITY \"A\" (USD) ACC","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","LU2129689514.USD":"FRANKLIN GLOBAL INCOME \"A\" (USD) INC"},"translate_title":"简介-Genmab表示Epcoritamab的3期试验未达到统计学意义","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABBV":0.9},"content_text":"BRIEF-Genmab Says Phase 3 Trial For Epcoritamab Did Not Reach Statistical SignificanceJan 16 (Reuters) - Genmab A/S GMAB.CO:GENMAB ANNOUNCES TOPLINE RESULTS FOR EPCORITAMAB (DUOBODY® CD3XCD20) FROM PHASE 3 EPCORE® DLBCL-1 TRIAL IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)GENMAB ANNOUNCES TOPLINE RESULTS FOR EPCORITAMAB (DUOBODY® CD3XCD20) FROM PHASE 3 EPCORE® DLBCL-1 TRIAL IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)GENMAB: STUDY OS DID NOT REACH STATISTICAL SIGNIFICANCEGENMAB: STUDY DEMONSTRATED AN OVERALL SURVIVAL OF HR: 0.96GENMAB - CO AND ABBVIE WILL ENGAGE WITH GLOBAL REGULATORY AUTHORITIES TO DISCUSS NEXT STEPSGENMAB: DATA IS ANTICIPATED IN 2026 FROM TWO PHASE 3 TRIALSSource text: ID:nGNX9tbFDFurther company coverage: GMAB.CO ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2604137679","isCrawlerRequest":true}